These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30797752)

  • 1. Long-term therapeutic success with multimodal therapy in aggressive prolactinoma.
    Iglesias P; Rodríguez Berrocal V; Pian H; Díez JJ
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):464-466. PubMed ID: 30797752
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined modalities of surgery, radiotherapy, radiosurgery and chemotherapy for invasive pituitary carcinoma.
    Tuleasca C; Messerer M; Levivier M; Daniel RT
    Ann Endocrinol (Paris); 2018 Apr; 79(2):82-85. PubMed ID: 29525560
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
    Zhang D; Way JS; Zhang X; Sergey M; Bergsneider M; Wang MB; Yong WH; Heaney AP
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1929-1936. PubMed ID: 30624667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
    Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
    World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.
    Marques B; Monteiro AR; Martins RG; Couto J; Rodrigues F; Ribeiro J
    Pancreas; 2020 Mar; 49(3):e19-e20. PubMed ID: 32168252
    [No Abstract]   [Full Text] [Related]  

  • 6. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P; Bohnen NI; Barkan AL; Shapiro B
    Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors.
    Raverot G; Vasiljevic A; Jouanneau E; Lasolle H
    Eur J Endocrinol; 2019 Aug; 181(2):C1-C3. PubMed ID: 31167164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant prolactinomas: the therapeutic approach.
    Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].
    Schäffler A
    Internist (Berl); 2006 Dec; 47(12):1215-6, 1218-20, 1222. PubMed ID: 17033781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin secreting pituitary carcinoma.
    Petterson T; MacFarlane IA; MacKenzie JM; Shaw MD
    J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1205-6. PubMed ID: 1479402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
    Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
    Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR.
    Sosa-Eroza E; Espinosa E; Ramírez-Rentería C; Mendoza V; Arreola R; Mercado M
    Endocrine; 2018 Aug; 61(2):343-348. PubMed ID: 29948930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of prolactin-secreting pituitary adenomas.
    Neal JH; Weiss MH
    West J Med; 1990 Nov; 153(5):546-7. PubMed ID: 2260295
    [No Abstract]   [Full Text] [Related]  

  • 16. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
    Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
    J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.
    Dai C; Sun B; Guan S; Wang W; Liu H; Li Y; Zhang J; Kang J
    BMC Endocr Disord; 2021 Oct; 21(1):217. PubMed ID: 34715828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
    Strowd RE; Salvatori R; Laterra JJ
    J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic resistance in a case of invasive macroprolactinoma.
    Schwarzstein D; García-Patterson A; Giménez G; Calaf J; Puig-Domingo M; Caixàs A; Matías-Guiu X; Webb SM
    J Endocrinol Invest; 1993 Jun; 16(6):443-7. PubMed ID: 8103781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary management of prolactinomas.
    Liu JK; Couldwell WT
    Neurosurg Focus; 2004 Apr; 16(4):E2. PubMed ID: 15191331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.